HERology | GLP-1 Hormones and Weight Loss

Why It Matters

GLP‑1 agonists offer women a clinically proven avenue to mitigate midlife metabolic risks and cardiovascular disease, reshaping treatment standards beyond diabetes and influencing future therapeutic strategies.

Key Takeaways

• GLP‑1 agonists boost gut‑brain satiety signaling, aiding weight loss.
• Women in midlife adopt GLP‑1s for metabolic health and aesthetics.
• Semaglutide reduces cardiovascular events by ~20% independent of weight loss.
• GLP‑1s may improve sleep apnea, inflammation, and hormone‑driven cancer risk.
• Ongoing research needed to integrate GLP‑1s with hormone therapy protocols.

Summary

The HERology podcast from Mount Sinai explores the surge of GLP‑1 hormone agonists, focusing on their role in weight management and broader health implications for midlife women. Host Dr. Joanne Stone and co‑hosts Dr. Anu Lala and Dr. Anna Barbieri discuss how these drugs, originally diabetes treatments, are reshaping women's health care.

GLP‑1s amplify the gut’s natural satiety signals, improve insulin sensitivity, slow gastric emptying, and reduce visceral fat. Women experience pronounced abdominal weight gain during perimenopause, prompting interest in GLP‑1s for both metabolic health and aesthetic reasons. Clinical data, such as the SELECT trial, show semaglutide cutting cardiovascular events by roughly 20% regardless of weight loss, while patients report dramatic weight reductions of up to 100 pounds.

Dr. Lala emphasizes that GLP‑1s “rev up” a hormone we already have, and Dr. Barbieri cites Mount Sinai research indicating 70 % of women gain significant weight in midlife. Real‑world observations include pharmacy ads for Zepbound, Mounjaro, Ozempic, and Wegovy, and anecdotal improvements in sleep apnea, joint pain, and even potential reductions in hormone‑driven cancer risk.

The conversation highlights a shifting paradigm: GLP‑1s are moving from niche diabetes therapy to a mainstream tool for cardiovascular protection, obesity management, and possibly adjunctive hormone therapy. Clinicians must navigate the thin line between medical necessity and cosmetic desire, while ongoing studies aim to clarify optimal integration with hormonal regimens and long‑term outcomes for women’s health.

Original Description

Advertising for GLP-1 hormones is everywhere now—but what are GLP-1s, and are they effective?

On this special edition of HERology, co-hosts Drs. Joanne Stone, Anna Barbieri, and Anu Lala explore the science—and controversy—behind GLP-1 medications. The hosts examine the complex intersection of hormones, aging, and weight gain—especially for women—and tackle essential details, such as:

The line between medical treatment and aesthetics;

The importance of lifestyle alongside medication;

How nutrition, movement, and sustainable habits remain foundational to health.

From disparities in access and social pressures to the role of prevention and policy, this conversation highlights both the promise and limitations of these widely discussed therapies.

HERology from the Mount Sinai Health System is dedicated to unpacking the science of women’s health—and helping listeners navigate it with clarity and confidence.

🎧 Subscribe to HERology and explore more podcast programming from Mount Sinai for expert conversations on the biggest issues in medicine, research, and patient care: https://www.youtube.com/playlist?list=PLCT7BA-HcHljLosQGv1XbpLc-IVpPBfEd

👉 To learn more about Mount Sinai’s services or to schedule an appointment with the Rowan Center, visit Mount Sinai online today: https://www.mountsinai.org/?pk_vid=174eeee090819798177342044977c34c